Asana BioSciences

Asana BioSciences is a clinical-stage biopharmaceutical company based in Bridgewater, New Jersey. Founded in 2014, the company employs 8 people and generates over $10,000 in annual revenue. Asana BioSciences focuses on developing novel, clinically differentiated products for cancer patients and those with inflammatory conditions. Their research and development efforts have resulted in seven successful Investigational New Drug (IND) applications filed and multiple clinical proof of concept studies completed in oncology and immunology/inflammation therapeutic categories. The company's lead immunology asset, Gusacitinib (ASN002), is currently in phase 3 development. Their lead oncology asset (ASN007 or ERAS-007) has completed phase 1 trials in cancer patients. Asana has also out-licensed or partnered with other biotech companies for the further development and commercialization of multiple drugs from its portfolio. Visit asanabio.com for more information.